Australian Doctor 9th Aug Issue | Page 16

16 OPINION

16 OPINION

9 AUGUST 2024 ausdoc . com . au
Insight

The death of good sense

Dr Sue Ieraci Emergency physician in Sydney , NSW .
The Senate ’ s excess deaths inquiry is

AS some of you following the news may know , the Australian Senate has been holding an inquiry into excess mortality .

It sounds important , and you could be fooled into thinking it is — that it is an examination into the lives that could be saved with better funding of general practice or public health initiatives .
But this inquiry was pushed by one of Clive Palmer ’ s politicians , a senator called Ralph Babet , who has long been concerned that the deaths resulting from the COVID-19 pandemic were not just a result of SARS-CoV-2 and its variants but of the vaccines themselves .
Clash of cultures
The inquiry ’ s remit is wider than that ,
of course .
There has been one public hearing so far , with expert witnesses brought before our elected representatives from a variety of organisations , including Professor Garry Jennings from the Heart Foundation and senior officials from the Department of Health and Aged Care as well as the Australian Bureau of Statistics ( ABS ).
The fascination for me lies in
witnessing the clash of two cultures with two very different fields of expertise : the political and the scientific .
The list of senators asking the questions included Mr Babet himself , Malcolm Roberts of Pauline Hanson ’ s One Nation and Gerard Rennick of the Liberal National Party of Queensland .
As you watched , you could see the spectacle of intended ‘ gotcha ’ questions being shot down with rational explanation and data .
At one point , one of the politicians shared their perspective with a witness from the ABS that their work was not very scientific .
Mr Babet also asked a bureau staffer whether , since the average life expectancy at birth for Australians was higher than the average age at death from COVID-19 , “ Do you find it strange that someone with COVID lives longer than someone without COVID ?” The ABS witness patiently explained how life expectancy at birth differs from age at death . What was remarkable was that they did this without the slightest hint of an eye-roll .
It is worth mentioning here that Mr Babet campaigned long and hard against the COVID-19 vaccine mandates introduced during the pandemic . He refused COVID-19 vaccines , reportedly describing them as an “ emergency-use gene therapy ”.
Red flags
But there were other witnesses too ,
perhaps more sympathetic to Mr Babet ’ s perspectives , including those from a group called the Australian Medical Professionals ’ Society .
You may not have heard about this group — it sprang up among a collection of professional organisations referred to as the ‘ red unions ’ after the COVID-19 pandemic requirements
Senator Ralph Babet in Parliament House last year .
were imposed on healthcare workers .
Ironically , these groups are neither red ( the concept arose from the Liberal National Party of Queensland ) nor registered unions .
Among their witnesses were an anaesthetist and a cardiologist — neither of whom , to my knowledge , held specialist expertise in pandemic management , vaccine science , infectious
diseases , immunology or public health .
One referred to their “ independent ” analysis of the initial Pfizer vaccine trials .
The same witness also used the phrase “ sudden adult death ”.
This is not a conventional term and appears to confuse the concepts of sudden unexplained death in infancy
( previously SIDS ) and sudden cardiac death in young adults ( mostly due to congenital cardiac conduction defects ).
Mystery solved
The errors in the Pfizer vaccine analysis
were clearly explained by scientist Dr Susan Oliver ( PhD ) in a YouTube video .
It was an ideologically driven inquiry , with some senators and witnesses having a barrow to push .
FAIRFAX
She said there was no significant difference in deaths in the vaccinated group versus unvaccinated group .
She also described the details of the trial participants who had died : one was a 58-year-old male with a background of previous MI and cardiomyopathy who died of an MI .
Analysis of the case found no link to vaccination .
This was not a mysterious sudden adult death ; it was a coronary death in a person with known coronary disease .
Another participant who died was a 51-year-old woman with a background of COPD and hypertension . She also died of an MI . Again , the cause was not a mystery .
Ideology over evidence
The inquiry has not been the sort of
retrospective analysis that looks at valid evidence in order to learn lessons and improve for the future .
It was an ideologically driven inquiry , with some senators and some witnesses having a barrow to push .
The expert witnesses who had analysed the data were admirable for their resigned patience in carefully answering questions and explaining methods .
The ideologically motivated witnesses , who were not experts , muddied the waters with evidence that had been debunked .
In Australia , detailed analysis on the impact of the COVID-19 pandemic has been carried out by teams within the Department of Health and Aged Care , the ABS and the Australian Institute of Health and Welfare , to name but a few .
These teams include some of the most skilled health data analysts in our nation .
The general consensus ? Excess deaths during the pandemic years were caused by a combination of direct deaths from SARS-CoV-2 infection , deaths precipitated by SARS- CoV-2 infection worsening other chronic diseases , and displacement of deaths from pandemic-management strategies , not by vaccines .
Dr Oliver ’ s YouTube video : bit . ly / 3zSUBW7

ESTROGEL ® PRO PRIMARY ADVERTISEMENT For her .

Medicine co-pack containing one pack of Estrogel ® ( estradiol hemihydrate ) plus one pack of Prometrium ® ( micronised progesterone ) for women with a uterus
PBS Information : These products are not available on the PBS .
Please review Product Information before prescribing , accessible at besins-healthcare . com . au / PI or 1800 BESINS ( 237 467 ), or by scanning the QR code :
Minimum Product Information Estrogel ( estradiol hemihydrate ) gel . Indications : Hormone replacement therapy ( HRT ) for estrogen deficiency symptoms in postmenopausal women . Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of , or contraindicated for , other medicinal products approved for the prevention of osteoporosis . The lowest effective dose should be used for the shortest duration . Contraindications : Known , past or suspected breast cancer ; Known or suspected estrogen-dependent malignant tumours ( e . g . endometrial cancer ); Undiagnosed genital bleeding ; Untreated endometrial hyperplasia ; Previous or current venous thromboembolism ( e . g . deep venous thrombosis , pulmonary embolism ); Known thrombophilic disorders ( e . g . protein C , protein S , or antithrombin deficiency ); Active or recent arterial thromboembolic disease ( e . g . angina , myocardial infarction ); Acute liver disease , or a history of liver disease as long as liver function tests have failed to return to normal ; Known or suspected pregnancy ; Lactation ; Known hypersensitivity to the active substances or to any of the excipients ; Porphyria . Precautions : Appraisal of the risks and benefits should be undertaken at least annually . Refer to full Product information ( PI ) for conditions which require supervision during treatment with Estrogel . Treatment should be withdrawn if the following occur , jaundice or deterioration in liver function ; significant increase in blood pressure ; new onset of migraine type headache ; pregnancy . Caution : endometrial hyperplasia and carcinoma , breast cancer , ovarian cancer , venous thromboembolism , coronary artery disease ( CAD ), ischaemic stroke , thyroid function , elderly , ALT elevations , paediatric use ( see full PI ). Interactions : use of concomitant skin medications , surface active agents or strong skin cleansers and detergents should be avoided at site of application , metabolism of estrogens may be increased by concomitant use of inducers of hepatic enzymes such as anticonvulsants ( phenobarbital , phenytoin , carbamezapine ) and anti-infectives ( rifampicin , rifabutin , nevirapine , efavirenz , ritonavir and nelfinavir ) and some herbal preparations ( St John ’ s wort ) reducing the effectiveness of estrogen . Estrogel as a transdermal administration might be less affected than other oral hormones by enzyme inducers . Concomitant use of estrogens with lamotrigine may decrease lamotrigine plasma concentrations . Caution is warranted for co-administration with hepatitis C virus ( HCV ) combination regimens ombitasvir / paritaprevir / ritonavir with or without dasabuvir and the regimen glecaprevir / pibrentasvir may cause greater than usual ALT elevations . Pregnancy Category B3 ; not for use in lactation . Adverse Effects : headache , nausea , abdominal pain , breast swelling / pain , breast enlargement , dysmenorrhea , menorrhagia , metrorraghia , leucorrhoea , endometrial hyperplasia , weight gain ( increase or decrease ), water retention with peripheral edema ( see full PI ). Dosage and Administration : Estrogel should be used daily on a continuous basis . Estrogel as an estrogen only product is indicated only for women without a uterus . In women with an intact uterus it is recommended to add a progestogen for at least 12 days of each month . Although some women will respond to 1.25 g daily ( 1 pump ), the usual starting dose is 2.5 g per day ( 2 pumps ). If after one month of treatment , effective relief of menopausal symptoms is not obtained the dosage may be increased to a maximum of 5 g ( 4 pumps ) ( see full PI ). The lowest effective dose should be used for maintenance therapy . The optimal daily maintenance dose needs to be reevaluated regularly ( e . g . annually ). Estrogel should only be continued for as long as the benefit outweighs the risk . The correct dose of gel should be dispensed and applied to clean , dry , intact areas of skin e . g . on the arms and shoulders , and / or inner thighs . The area of application should be as large as possible . Refer to Full Product Information before prescribing .
Minimum Product Information Prometrium ( oral , micronised progesterone ) Indications : menstrual irregularities ; adjunctive use with an estrogen in postmenopausal women with an intact uterus . Contraindications : known allergy / hypersensitivity to progesterone or excipients ; severe hepatic dysfunction ; undiagnosed vaginal bleeding ; known missed abortion / ectopic pregnancy ; mammary / genital tract carcinoma ; thromboembolic disorders ; thrombophlebitis ; cerebral haemorrhage ; porphyria . Clinically Significant Precautions : not a treatment for premature labour ; not a contraceptive ; discontinue if unexplained visual loss / changes , proptosis , diplopia , papilloedema , retina vascular lesions or migraine ; use caution in conditions affected by fluid retention and history of depression , diabetes , hepatic dysfunction , migraine , photosensitivity and during lactation ; increased risk of breast cancer and venous thromboembolism with estrogen concomitant therapy ( refer estrogen PI ); may cause drowsiness ; may affect laboratory test results . Clinically Significant Interactions : caution with P450 enzyme inducers and inhibitors ; may increase antidiabetic medication ; bioavailability may be reduced by smoking and increased by alcohol abuse . Very Common and Common Adverse Effects : menstrual disturbances ; headache . d1 – d25 . Secondary amenorrhoea : 400mg / d for 10d . Ovulation disorders / anovulation : 200 – 300mg for 10d ( d17 – d26 , inclusive ).
Estrogel ® and Prometrium ® are registered trademarks of Besins Healthcare . Besins Healthcare Australia Pty Ltd ABN 68 164 882 062 . Suite 5.02 , 12 Help Street , Chatswood NSW 2067 . Office phone ( 02 ) 9904 7473 . For medical information call 1800 BESINS ( 237 467 ). www . besins-healthcare . com . au EPR-EST-PRM-1969 January 2024